How to appeal a CareFirst BCBS genetic testing denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

CareFirst BCBS-specific note: BCBS licensee for Maryland, DC, and northern Virginia (~3.5M members). Operates as non-profit. Appeals jurisdiction depends on policy issue location — MIA (MD), DISB (DC), or SCC Bureau of Insurance (VA). CVS Caremark is the PBM.

What CareFirst BCBS's policy requires for genetic testing

Cited policy: BCBSA Evidence Street + Avalon Healthcare Solutions Trusted Lab Network (most BCBS); Anthem uses AIM/Carelon

BCBSA TEC + Avalon lab management policies; NCCN-aligned.

How CareFirst BCBS denies genetic testing — and how to counter it

Where CareFirst BCBS pushes back: 1) 'Lab not in Avalon Trusted Lab Network'; 2) 'Test panel exceeds covered gene set'; 3) 'NIPT denied — singleton low-risk; quad screen first-line' (older); 4) 'MRD testing (Signatera) experimental outside specific tumor types'.

Counter-arguments that hold up: Confirm Avalon network status; reroute to in-network lab if denial is purely contractual. NCCN footnote endorses comprehensive panels when phenotype overlaps syndromes; LaDuca 2020 panel data. USPSTF + ACA §2713 for BRCA. Signatera: MolDX L39167 (CRC MRD); Reinert 2019 JAMA Oncol; NCCN colon ca footnote on ctDNA.

What CareFirst BCBS typically denies for genetic testing

Across CareFirst BCBS's commercial and Medicare books, denials cluster around a small number of patterns. For genetic testing, expect:

• DC/MD/VA cross-jurisdiction issues
• Step therapy on specialty drugs via CVS Caremark
• Behavioral health network adequacy
• BlueChoice HMO referral denials

Treatments most often denied in this category

These are the genetic testing treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Hereditary cancer panel
• BRCA1/2
• Lynch panel
• Cardiogenetic
• WES / WGS
• Carrier screening

How to submit the appeal to CareFirst BCBS

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document CareFirst BCBS cited in the denial.
3. File the appeal through CareFirst BCBS's portal (members: https://member.carefirst.com ; providers: https://provider.carefirst.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MD, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See CareFirst BCBS's prior-authorization criteria by drug: CareFirst BCBS PA criteria on ApprovalHelp.